Expression Of PTTG And COX2 In Breast Invasive Ductal Carcinoma And Their Clinical Significance

[OBJECTIVE] To evaluate the expression of pituitary tumor-transforming gene (PTTG) and cyclooxygenase-2 (COX2) in breast invasive ductal carcinoma and their clinical significance.[METHODS] One hundred and four cases of breast invasive ductal carcinoma were collected from Department of Pathology Shandong University Second Affiliation Hospital from 2002-2005.The samples were fixed in 10% formalin and paraffin embedded. All archival haematoxylin and eosin-stained sections were reviewed to confirm the diagnosis. Immunohistochemistry was used to determine the expression of PTTG and COX2. All the data were analyzed by the chi-square test using SPSS14.0 software for windows.[RESULTS] The positive expression of PTTG was 95 of 104 invasive ductal carcinomas. The positive rate was 91%. Of which 41 (39%) were weak expression and 51 (52%) was high expression. The positive expression of COX2 was 70 of 104 invasive ductal carcinomas. The positive rate was 67%. Of which 53 (51%) were weak expression and 17 (16%) was high expression. There were significant association between PTTG expression and histological grade and tumor size,with increased PTTG staining correlating with higher histological grade. There were no significant association between PTTG expression and the age, lymphnode metastasis, ER, PR, HER2 status. The espression of COX2 correlated with ER status, tumor size, histological grade, lymphnode metastasis. The espression of COX2 is higher in ER(+) group than in ER(-) group. There were no significant association between COX2 and PTTG expression.[CONCLUSION] The expression of PTTG in breast invasive ductal carcinoma had a correlation with low differentiation degree. The expression of COX2 correlated with low differentiation degree and poor prognostic factors such as lymphnode metastasis. Co-evaluating the expression of PTTG and COX2 in breast invasive ductal carcinoma may play an important role in prediction of the prognosis of breast invasive ductal carcinoma.